Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib.
Josef J. Fox
No relevant relationships to disclose
Eric C. Haupt
No relevant relationships to disclose
John Humm
No relevant relationships to disclose
Karen A. Autio
No relevant relationships to disclose
Dana E. Rathkopf
No relevant relationships to disclose
Hebert Alberto Vargas
No relevant relationships to disclose
Heiko Schöder
No relevant relationships to disclose
Hedvig Hricak
No relevant relationships to disclose
Steven M. Larson
No relevant relationships to disclose
Howard I. Scher
No relevant relationships to disclose
Michael J. Morris
No relevant relationships to disclose